Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer

BJU International

Volumn 98, Issue 1, 2006, Pages 11-19

  Hammerer, Peter G ^a,e   Kattan, Michael W ^d   Mottet, Nicolas ^b   Prayer Galetti, Tommaso ^c  

^a Academic Hospital   (Germany)

^b Department of Clinique Mutualiste ^*  (France)

^c UNIVERSITY OF PADOVA   (Italy)

^d LERNER RESEARCH INSTITUTE   (United States)

^e Braunschweig Hospital   (Germany)

Author keywords

Diagnosis; Disease progression; Nomograms; Patient education; Prostate cancer; PSA; Risk assessment

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ACINAR CELL; ANDROGEN DEPRIVATION THERAPY; AWARENESS; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DISEASE MARKER; DOCTOR PATIENT RELATION; EARLY DIAGNOSIS; ERECTILE DYSFUNCTION; EUROPE; EVIDENCE BASED MEDICINE; EXTERNAL BEAM RADIOTHERAPY; FEAR; FRACTURE; HIGH RISK PATIENT; HORMONE INHIBITION; HOT FLUSH; HUMAN; INCONTINENCE; INFORMED CONSENT; LIFE EXPECTANCY; MEASUREMENT; MEDICAL DECISION MAKING; METASTASIS; NOMOGRAM; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; STATISTICAL MODEL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; VALIDATION PROCESS;

HUMANS; MALE; NOMOGRAMS; PATIENT EDUCATION; POSTOPERATIVE CARE; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 33745101490     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06177.x     Document Type: Short Survey

References (76)

1. Black RJ Bray F Ferlay J Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997 33: 1075 107
2. Ross PL Scardino PT Kattan MW. A catalog of prostate cancer nomograms. J Urol 2001 165: 1562 8
3. Sakr WA Grignon DJ Crissman JD et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994 8: 439 43
4. Schmid HP McNeal JE Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993 71: 2031 40
5. Smith RA von Eschenbach AC Wender R et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, endometrial cancers. CA Cancer J Clin 2001 51: 38 75
6. Boccon-Gibod L Djavan WB Hammerer P et al. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 2004 58: 382 90
7. Cooperberg MR Broering JM Litwin MS Lubeck DP Mehta SS, CaPSURE Investigators. The contemporary management of prostate cancer in the United States: lessons form the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 2004 171: 1393 401
8. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer. initial results of the Medical Research Council Trial. Br J Urol 1997 79: 235 46
9. Stamey TA Caldwell M McNeal JE Nolley R Hemenez M Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004 172: 1297 301
10. Brett J Watson E Hewitson P et al. PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK. BMC Fam Pract 2005 6: 24
11. Oefelein MG Resnick MI. Effective testosterone suppression for patients with prostate cancer: is there a best castration? Urology 2003 62: 207 13
12. Djavan B Remzi M Zlotta AR et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 2002 60 ( Suppl. 4 4 9
13. Catalona WJ Partin AW Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998 279: 1542 7
14. Roehl KA Antenor JA Catalona WJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6-4.0 ng/mL range. J Urol 2002 168: 922 5
15. Gann PH Ma J Catalona WJ Stampfer MJ. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J Urol 2002 167: 2427 34
16. Catalona WJ Mikolajczyk SD Linton HJ et al. ProPSA helps to detect more aggressive prostate cancer in the 2-4 ng/ml PSA range. J Urol 2003 169: 290, A1128
17. Lein M Semjonow A Graefen M et al. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. J Urol 2005 174: 2150 3
18. D'Amico AV Moul JW Carroll PR Sun L Lubeck D Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003 95: 1376 83
19. Ciatto S Bonardi R Lombardi C Zappa M Gervasi G Cappelli G. Analysis of PSA velocity in 1666 healthy subjects undergoing total PSA determination at two consecutive screening rounds. Int J Biol Markers 2002 17: 79 83
20. Schroder FH Raaijmakers R Postma R van der Kwast TH Roobol MJ. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. J Urol 2005 174: 489 94
21. Gancarczyk K Wu H McLeod DG et al. Using the percentage of biopsy cores positive for cancer, pre-treatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: The Center for Prostate Disease Research nomograms. Urology 2003 61: 589 95
22. D'Amico AV Whittington R Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998 280: 969 74
23. Hanlon AL Diratzouian H Hanks GE. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 2002 53: 297 303
24. Roberts SG Blute ML Bergstralh EJ Slezak JM Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001 76: 576 81
25. Bates AT Pickles T Paltiel C. PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy. Int J Radiat Oncol Biol Phys 2005 62: 148 53
26. Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol 2003 13: 111 6
27. Amling CL Bergstralh EJ Blute ML Slezak JM Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001 165: 1146 51
28. Scher HI Eisenberger M D'Amico AV et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004 22: 537 56
29. Pound CR Partin AW Eisenberger MA Chan DW Pearson JD Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 281: 1591 7
30. Amling CL Blute ML Bergstralh EJ Seay TM Slezak J Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000 164: 101 5
31. Partin AW Eisenberger MA Sinibaldi VJ Humphreys E Mangold LA Walsh PC. Prostate specific antigen doubling time (PSADT) predicts for distant failure and prostate cancer specific survival (PCSS) in men with biochemical relapse after radical prostatectomy (RP). J Clin Oncol 2004 22 ( Suppl. 4555
32. D'Amico AV Chen MH Roehl KA Catalona WJ. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 2005 23: 4975 9
33. Schmid HP Semjonow A Maibach R. Prostate-specific antigen doubling time: a potential surrogate end point in hormone-refractory prostate cancer. J Clin Oncol 1999 17: 1645 6
34. Albertsen PC Hanley JA Penson DF Fine J. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 2004 171: 2221 5
35. D'Amico AV Chen MH Roehl KA Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004 351: 125 35
36. Brawer MK Benson MC Djavan B et al. Prostate serum markers. In Murphy G Khoury S Parin A Denis L, 2nd International Consultation on Prostate Cancer, June 27-29, 1999. Paris: Health Publications Ltd, 2000
37. Kuban D Thames H Levy L et al. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? Int J Radiat Oncol Biol Phys 2005 61: 409 14
38. Horwitz EM Thames HD Kuban DA et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol 2005 173: 797 802
39. Bolla M Collette L Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002 360: 103 6
40. Ash D Flynn A Battermann J de Reijke T Lavagnini P Blank L ESTRA/EAU Urological Brachytherapy Group; EORTC Radiotherapy Group. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000 57: 315 21
41. Blasko JC Grimm PD Sylvester JE Badiozamani KR Hoak D Cavanagh W. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000 46: 839 50
42. Critz FA Levinson AK Williams WH Holladay CT Griffin VD Holladay DA. Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy. J Urol 1999 161: 1199 205
43. Smith JA Lange PH Janknegt RA Abbou CC deGery A. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. J Urol 1997 157: 1329 34
44. Smith DC Dunn RL Strawderman MS Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998 16: 1835 43
45. Mason MD. Development of bone metastases from prostate cancer: First results of the MRC PR04 trial (ISCRTN 61384873). J Clin Oncol 2004 22 ( Suppl. Abstract 4511
46. Wolf AM Nasser JF Wolf AM Schorling JB. The impact of informed consent on patient interest in prostate-specific antigen screening. Arch Intern Med 1996 156: 1333 6
47. Shah JB Reese AC McKiernan JM Benson MC. PSA updated: still relevant in the new millennium? Eur Urol 2005 47: 427 32
48. Chan EC Sulmasy DP. What should men know about prostate-specific antigen screening before giving informed consent? Am J Med 1998 105: 266 74
49. Miles BJ Giesler B Kattan MW. Recall and attitudes in patients with prostate cancer. Urology 1999 53: 169 74
50. Wolf AM Philbrick JT Schorling JB. Predictors of interest in prostate-specific antigen screening and the impact of informed consent: what should we tell our patients? Am J Med 1997 103: 308 14
51. O'Dell KJ Volk RJ Cass AR Spann SJ. Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions? J Fam Pract 1999 48: 682 8
52. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004 5: 101 6
53. Smith MR. Complementary and alternative therapies for advanced prostate cancer. Haematol Oncol Clin North Am 2001 15: 559 71
54. Klotz LH Goldenberg SL Jewett MA et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003 170: 791 4
55. Roach M DeSilvio M Lawton C et al. Radiation Therapy Oncology Group 9413. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation therapy oncology Group 9413. J Clin Oncol 2003 21: 1904 11
56. Loblaw DA Mendelson DS Talcott JA et al. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004 14: 2927 41
57. Dillioglugil O Leibman BD Leibman NS Kattan MW Rosas AL Scardino PT. Risk factors for complications and morbidity after radical retropubic prostatectomy. J Urol 1997 157: 1760 7
58. Walsh PC. Anatomic radical prostatectomy: evolution of the surgical technique. J Urol 1998 160: 2418 24
59. Bill-Axelson A Holmberg L Ruutu M et al. Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005 352: 1977 84
60. Steineck G Helgesen F Adolfsson J et al. Scandinavian Prostatic Cancer Group Study Number 4. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002 347: 790 6
61. Aus G Abbou CC Bolla M et al. EAU Guidelines on prostate cancer. Eur Urol 2005 48: 546 51
62. Clark JA Wray NP Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol 2001 19: 72 80
63. Kattan MW. When and how to use informatics tools in caring for urologic patients. Nat Clin Pract Urol 2005 2: 183 90
64. Kattan MW Eastham JA Stapleton AM Wheeler TM Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998 90: 766 71
65. Kattan MW Zelefsky MJ Kupelian PA Scardino PT Fuks Z Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000 18: 3352 9
66. Graefen M Karakiewicz PI Cagiannos I et al. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol 2002 20: 951 6
67. Yanke BV Gonen M Scardino PT Kattan MW. Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. J Urol 2005 173: 421 4
68. Ohori M Kattan MW Koh H et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004 171: 1844 9
69. Koh H Kattan MW Scardino PT et al. A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol 2003 170: 1203 8
70. Cagiannos I Karakiewicz P Eastham JA et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003 170: 1798 803
71. Kattan MW Eastham JA Wheeler TM et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003 170: 1792 7
72. Kattan MW Potters L Blasko JC et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001 58: 393 9
73. Bianco FJ Kattan MW Scardino PT Powell IJ Pontes JE Wood DP Jr. Radical prostatectomy nomograms in black American men. accuracy and applicability. J Urol 2003 170: 73 7
74. Smaletz O Scher HI Small EJ et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002 20: 3972 82
75. Halabi S Small EJ Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003 21: 1232 7
76. Stephenson AJ Scardino PT Eastham JA et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005 23: 7005 12